Licensing
Proven expertise to multiply your impact:
- Scale your capacity to shorten setup periods and reduce development times
- Bolster your pharmaceutical projects with viral vector engineering and manufacturing and cell line engineering
- Expand your offerings by licensing IP like Pin-point (TM) Base Editing Platform, LentiBOOST® Viral vector-based gene editing, and more
For research use only. Not for use in diagnostic procedures.
Pin-point Base Editing Platform
Novel editing system for a more controlled approach to gene disruption and base correction with the potential for multiplex gene editing capabilities.
Gene Delivery Systems
Our strong IP portfolio across lentiviral vectors, AAVs, and adenoviruses supports the entire gene and cell therapy (GCT) value chain from discovery to commercialization and is accessible to industrial partners and academic institutions at the forefront of the gene and cell therapy revolution.
Gene Expression Systems
Streamlining biotherapeutic development with gene expression systems, providing speed, reliability, and adaptability at all stages of the process.
Virus Screening
Offering promising tools to accelerate high-throughput screening projects aiming to identify lead candidates.
